Analysis of the expression of nine secreted matrix metalloproteinases and their endogenous inhibitors in the brain of mice subjected to ischaemic stroke

Summary

Matrix metalloproteinases (MMPs) are a family of more than twenty secreted and cell-surface endopeptidases. Among them, MMP2, MMP3 and MMP9 are involved in blood-brain barrier injury and neuronal death after cerebral ischaemia. On the other hand, very little is known about the expression of the other secreted MMPs. Herein, we compared the global changes in MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP12 and MMP13, and their endogenous inhibitors TIMP1 and TIMP2, both at the mRNA and protein levels, during the hyperacute (6 h), acute (24 h) and subacute (72 h) stages following transient focal cerebral ischaemia and treatment with recombinant tissue plasminogen activator (rtPA). We observed a significant increase in MMP1, MMP2, MMP9, MMP10, MMP13 and TIMP1 levels during the acute stage of reperfusion, which was further amplified during the subacute stage for MMP1, MMP2, MMP10 and TIMP1. In general, no change of MMP3, MMP7, MMP8, MMP12 and TIMP2 was observed. However, rtPA treatment induced a rapid increase in MMP1/TIMP2, MMP2/TIMP2, MMP8/TIMP2 and MMP9/TIMP2 ratios during the hyperacute stage of reperfusion compared to saline treatment, which may have potential implications in the early disruption of the blood-brain barrier after rtPA treatment.

Keywords

Brain ischaemia - MMP - TIMP - tPA - animal model

• References

• 1 Gasche Y, Soccal PM, Kanemitsu M. et al. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischaemic brain. Front Biosci 2006; 11: 1289-1301.
• 2 Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
• 3 Rodriguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 2010; 1803: 39-54.
• 4 Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010; 1803: 55-71.
• 5 Justicia C, Panes J, Sole S. et al. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischaemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab 2003; 23: 1430-1440.
• 6 Planas AM, Sole S, Justicia C. Expression and activation of matrix metalloproteinase-2 and −9 in rat brain after transient focal cerebral ischaemia. Neurobiol Dis 2001; 08: 834-846.
• 7 Gidday JM, Gasche YG, Copin JC. et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischaemia. Am J Physiol Heart Circ Physiol 2005; 289: H558-568.
• 8 Copin JC, Merlani P, Sugawara T. et al. Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp Neurol 2008; 213: 196-201.
• 9 Rosenberg GA, Cunningham LA, Wallace J. et al. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 2001; 893: 104-112.
• 10 Sole S, Petegnief V, Gorina R. et al. Activation of matrix metalloproteinase-3 and agrin cleavage in cerebral ischaemia/reperfusion. J Neuropathol Exp Neurol 2004; 63: 338-349.
• 11 Suzuki Y, Nagai N, Umemura K. et al. Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost 2007; 05: 1732-1739.
• 12 Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998; 29: 2189-2195.
• 13 Rosenberg GA, Navratil M, Barone F. et al. Proteolytic cascade enzymes increase in focal cerebral ischaemia in rat. J Cereb Blood Flow Metabol 1996; 16: 360-366.
• 14 Romanic AM, White RF, Arleth AJ. et al. Matrix metalloproteinase expression increases after cerebral focal ischaemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998; 29: 1020-1030.
• 15 Lakhan SE, Kirchgessner A, Tepper D. et al. Matrix metalloproteinases and blood-brain barrier disruption in acute ischaemic stroke. Front Neurol 2013; 04: 32.
• 16 Cuadrado E, Rosell A, Penalba A. et al. Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. J Proteome Res 2009; 08: 3191-3197.
• 17 Ning M, Sarracino DA, Buonanno FS. et al. Proteomic Protease Substrate Profiling of tPA Treatment in Acute Ischaemic Stroke Patients: A Step Toward Individualizing Thrombolytic Therapy at the Bedside. Transl Stroke Res 2010; 01: 268-275.
• 18 Lees KR, Bluhmki E, von Kummer R. et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
• 19 Vivien D, Gauberti M, Montagne A. et al. Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab 2011; 31: 2119-2134.
• 20 Tsuji K, Aoki T, Tejima E. et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 up-regulation after focal cerebral ischaemia. Stroke 2005; 36: 1954-1959.
• 21 Wang X, Tsuji K, Lee SR. et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischaemic stroke. Stroke 2004; 35 (11) (Suppl. 01) 2726-2730.
• 22 Jickling GC, Liu D, Stamova B. et al. Hemorrhagic transformation after ischaemic stroke in animals and humans. J Cereb Blood Flow Metab 2014; 34: 185-199.
• 23 Copin JC, Bengualid DJ, Da Silva RF. et al. Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischaemia in mouse. Eur J Neurosci 2011; 34: 1085-1092.
• 24 Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischaemia in rats. Stroke 2002; 33: 831-836.
• 25 Copin JC, da Silva RF, Fraga-Silva RA. et al. Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischaemic stroke, but not brain injury in mice. J Cereb Blood Flow Metab 2013; 33: 490-498.
• 26 Gubern C, Hurtado O, Rodriguez R. et al. Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral ischaemia. BMC Mol Biol 2009; 10: 57.
• 27 Clark IM, Swingler TE, Sampieri CL. et al. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008; 40: 1362-1378.
• 28 Li L, Li H. Role of microRNA-mediated MMP regulation in the treatment and diagnosis of malignant tumors. Cancer Biol Ther. 2014 in press
• 29 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
• 30 Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene 2006; 25: 6170-6175.
• 31 Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol 2013; 48: 222-272.
• 32 Zheng X, Chopp M, Lu Y. et al. MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. Cancer Lett 2013; 329: 146-154.
• 33 Garbacki N, Di Valentin E, Piette J. et al. Matrix metalloproteinase 12 silencing: a therapeutic approach to treat pathological lung tissue remodeling?. Pulm Pharmacol Ther 2009; 22: 267-278.
• 34 Vemuganti R. All’s well that transcribes well: Non-coding RNAs and post-stroke brain damage. Neurochem Int 2013; 63: 438-449.
• 35 Jin R, Yang G, Li G. Inflammatory mechanisms in ischaemic stroke: role of inflammatory cells. J Leukoc Biol 2010; 87: 779-789.
• 36 Toft-Hansen H, Nuttall RK, Edwards DR. et al. Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J Immunol 2004; 173: 5209-5218.
• 37 Gasche Y, Fujimura M, Morita-Fujimura Y. et al. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischaemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 1999; 19: 1020-1028.
• 38 Nagel S, Sandy JD, Meyding-Lamade U. et al. Focal cerebral ischaemia induces changes in both MMP-13 and aggrecan around individual neurons. Brain Res 2005; 1056: 43-50.
• 39 Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix metalloproteinase-9 as a marker for acute ischaemic stroke: a systematic review. J Stroke Cerebrovasc Dis 2011; 20: 47-54.
• 40 Cuadrado E, Rosell A, Borrell-Pages M. et al. Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischaemia. J Cereb Blood Flow Metab 2009; 29: 398-410.
• 41 Rosell A, Alvarez-Sabin J, Arenillas JF. et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 2005; 36: 1415-1420.
• 42 Kouwenhoven M, Carlstrom C, Ozenci V. et al. Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke. J Clin Immunol 2001; 21: 365-375.
• 43 Svedin P, Hagberg H, Mallard C. Expression of MMP-12 after neonatal hypoxicischaemic brain injury in mice. Dev Neurosci 2009; 31: 427-436.
• 44 Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 1995; 248: 496-510.
• 45 Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol 2013; 13: 649-665.
• 46 Verstappen J, Von den Hoff JW. Tissue inhibitors of metalloproteinases (TIMPs): their biological functions and involvement in oral disease. J Dent Res 2006; 85: 1074-1084.
• 47 Fujimoto M, Takagi Y, Aoki T. et al. Tissue inhibitor of metalloproteinases protect blood-brain barrier disruption in focal cerebral ischaemia. J Cereb Blood Flow Metab 2008; 28: 1674-1685.